ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
8 001,80
-0,48%
Dow Jones
38 798,99
-0,22%
DAX
18 557,27
-0,48%
Brent Oil
79,395
0,00%
Bitcoin
69 246,67
-0,12%
Registration Strip Icon for alerts Inscrivez-vous pour des alertes en temps réel, un portefeuille personnalisé et des mouvements de marché.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Synaptogenix Inc (SNPX)

  7. Synaptogenix Inc (SNPX) Actualités

SNPX

Synaptogenix (SNPX)

Synaptogenix Inc
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:SNPX
DateHeureSourceTitreSymboleSociété
15/05/202423h03Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:SNPXSynaptogenix Inc
07/05/202415h00PR Newswire (US)Synaptogenix Applauds DEA Proposal to Reclassify Cannabis and Shares Expected Benefits to Cannasoul for Cannabinoid-Based Drug DiscoveryNASDAQ:SNPXSynaptogenix Inc
24/04/202415h15PR Newswire (US)Synaptogenix Regains Compliance with Nasdaq Minimum Bid Price Requirement for Continued ListingNASDAQ:SNPXSynaptogenix Inc
09/04/202415h15PR Newswire (US)Synaptogenix Increases Stake in Innovative Psilocybin Drug Discovery Company through its Partnership with Cannasoul AnalyticsNASDAQ:SNPXSynaptogenix Inc
03/04/202414h00PR Newswire (US)Synaptogenix Announces Reverse Stock Split to Maintain Nasdaq ListingNASDAQ:SNPXSynaptogenix Inc
06/02/202416h16Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:SNPXSynaptogenix Inc
21/12/202323h00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:SNPXSynaptogenix Inc
19/12/202315h00PR Newswire (US)Synaptogenix President Daniel L. Alkon, M.D. Honored for Scientific Presentation at USC-Sponsored Forum on Age-Related Diseases and Neurodegenerative DisordersNASDAQ:SNPXSynaptogenix Inc
06/12/202315h00PR Newswire (US)Synaptogenix Joins Leading Neuroscientists and Academics as Speaker at USC-Sponsored Forum on Age-Related Diseases including Alzheimer'sNASDAQ:SNPXSynaptogenix Inc
14/11/202323h05Edgar (US Regulatory)Form ARS - Annual Report to Security HoldersNASDAQ:SNPXSynaptogenix Inc
13/11/202323h00Edgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsNASDAQ:SNPXSynaptogenix Inc
03/11/202322h00Edgar (US Regulatory)Form PRE 14A - Other preliminary proxy statementsNASDAQ:SNPXSynaptogenix Inc
02/11/202314h00PR Newswire (US)Synaptogenix Acquires Significant Stake in Cannasoul Analtyics Ltd. Co-founded by The Technion - Israel Institute of TechnologyNASDAQ:SNPXSynaptogenix Inc
26/09/202315h00PR Newswire (US)Synaptogenix Announces Peer-Reviewed Publication of NIH-Sponsored Phase 2 Clinical Trial Results Demonstrating Safe, Significant, and Persistent Benefits of Bryostatin-1 in Advanced Alzheimer's DiseaseNASDAQ:SNPXSynaptogenix Inc
07/09/202315h00PR Newswire (US)Bryostatin-1 from Synaptogenix Shows Statistically Significant Results as an ALS Treatment in Pre-Clinical Independent StudyNASDAQ:SNPXSynaptogenix Inc
19/07/202315h00PR Newswire (US)Synaptogenix and Cleveland Clinic to Submit Investigational New Drug (IND) Application to FDA for Clinical Trial of Bryostatin-1 in Multiple SclerosisNASDAQ:SNPXSynaptogenix Inc
13/07/202315h00PR Newswire (US)Synaptogenix Abstract Highlighting Bryostatin-1 Benefits in Severe Alzheimer's Disease Accepted for Presentation at 11th International Brain Research Organization World Congress of NeuroscienceNASDAQ:SNPXSynaptogenix Inc
22/06/202323h15Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:SNPXSynaptogenix Inc
15/05/202322h51Edgar (US Regulatory)Quarterly Report (10-q)NASDAQ:SNPXSynaptogenix Inc
31/03/202322h23Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:SNPXSynaptogenix Inc
21/03/202322h24Edgar (US Regulatory)Annual Report (10-k)NASDAQ:SNPXSynaptogenix Inc
07/03/202315h00PR Newswire (US)Synaptogenix Provides Corporate Update and Outlines Potential Business OpportunitiesNASDAQ:SNPXSynaptogenix Inc
18/01/202322h29Edgar (US Regulatory)Amended Statement of Ownership (sc 13g/a)NASDAQ:SNPXSynaptogenix Inc
28/12/202222h16Edgar (US Regulatory)Proxy Statement - Notice of Shareholders Meeting (preliminary) (pre 14a)NASDAQ:SNPXSynaptogenix Inc
28/12/202212h03Edgar (US Regulatory)Notice of Effectiveness (effect)NASDAQ:SNPXSynaptogenix Inc
16/12/202215h00PR Newswire (US)Synaptogenix Announces Topline Results from NIH-Sponsored Phase 2 Clinical Trial of Bryostatin-1 for Advanced Alzheimer's DiseaseNASDAQ:SNPXSynaptogenix Inc
18/11/202215h00PR Newswire (US)Synaptogenix Announces $15 Million Private Placement with Existing InvestorsNASDAQ:SNPXSynaptogenix Inc
19/10/202215h00PR Newswire (US)Synaptogenix to Present at ThinkEquity Investor Conference on October 26, 2022NASDAQ:SNPXSynaptogenix Inc
28/09/202217h50PR Newswire (US)Synaptogenix Welcomes Lecanemab Phase 3 Trial ResultsNASDAQ:SNPXSynaptogenix Inc
25/08/202222h34Edgar (US Regulatory)Additional Proxy Soliciting Materials (definitive) (defa14a)NASDAQ:SNPXSynaptogenix Inc
 Showing the most relevant articles for your search:NASDAQ:SNPX

Dernières Valeurs Consultées

NYSE
COF-H
Capital One Financial
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés